In patients with recurrent GBM, the percentage of programmed death ligand 1 (PD-L1; diffuse/fibrillary PD-L1 expression: PD-L1 detected in non-necrotic areas) expression was 72.2%, whereas the percentage of patients with moderate or high expression of PD-L1 (5% or more) was 16.7% [6]. This evidence concerns the gene CD274 and glioblastoma.